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Diagnostic Accuracy and Prognostic Relevance
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Natriuretic Peptides: A Review
Aldo Clerico* and Michele Emdin
Background: The pathophysiologic and clinical rele-
vance of cardiac natriuretic hormone (CNH) assays has
been investigated in numerous experimental and clini-
cal studies. Authors have sought to evaluate the diag-
nostic accuracy and prognostic relevance of the mea-
surement of CNHs according to evidence-based
laboratory medicine principles.
Methods: In June 2003, we ran a computerized literature
search on National Library of Medicine using keywords
“ANP” and “BNP” and found more than 12 300 and 1200
articles, respectively. A more refined search with key-
words “ANP or BNP assay” extracted 7000 and 800
articles, respectively. Only studies specifically designed
to evaluate the diagnostic accuracy and prognostic rele-
vance of CNH measurements were selected from this
huge mass of articles to be discussed in this review.
Content: Several studies suggested that CNH assays
may be clinically useful for the screening and classifi-
cation of patients with heart failure, as a prognostic
marker in cardiovascular disease, in the follow-up of
patients with heart failure, and because they may reduce
the need for further cardiac investigation. However, it is
difficult to compare even the best-designed studies
because not only did the authors evaluate different
populations, they also used different gold standards.
Conclusions: CNH assays and conventional diagnostic
work-ups provide complementary information for eval-
uation of the presence and severity of cardiac dysfunc-
tion and clinical disease. Several aspects of CNH assays
are still to be elucidated, and further work is needed to
carefully assess their diagnostic accuracy and prognostic
value in cardiac disease.
© 2004 American Association for Clinical Chemistry
Cardiomyocytes produce and secrete a family of related
peptide hormones, named cardiac natriuretic hormones
(CNHs),1 that have potent diuretic, natriuretic, and vas-
cular smooth muscle-relaxing effects and also carry out
complex interactions with the neurohormonal system, as
reviewed recently (1–7).
Although the role of CNHs in the identification and
management of individuals with asymptomatic ventricu-
lar dysfunction remains to be fully clarified (8 ), the
potential clinical usefulness of assays for CNHs [espe-
cially B-type natriuretic peptide (BNP) or the NH2-termi-
nal fragment of proBNP (NT-proBNP)] for screening of
heart disease (9 ), for stratification of patients with con-
gestive heart failure (HF) (10 ), for detection of left ven-
tricular systolic and/or diastolic dysfunction (11 ), and for
differential diagnosis of dyspnea (12, 13) has been con-
firmed more recently. Furthermore, the Task Force of the
European Society of Cardiology for the Diagnosis and
Treatment of Chronic HF recommended that a CNH assay
should be included in the first step of the algorithm for the
diagnosis of HF along with electrocardiography (ECG)
and chest x-rays (14 ).
Although several reviews have recently been pub-
lished on the biochemical characteristics and pathophys-
iologic relevance of CNHs (1–7), a review specifically
CNR Institute of Clinical Physiology, Laboratory of Cardiovascular Endo-
crinology, Pisa, Italy.
*Address correspondence to this author at: Laboratory of Cardiovascular
Endocrinology and Cell Biology, CNR Institute of Clinical Physiology, Via
Trieste 41, 56126 Pisa, Italy. Fax 39-0585-493601; e-mail clerico@ifc.cnr.it.
Received July 19, 2003; accepted October 9, 2003.
Previously published online at DOI: 10.1373/clinchem.2003.024760
1 Nonstandard abbreviations: CNH, cardiac natriuretic hormone; BNP,
brain (or B-type) natriuretic peptide, COOH-terminal fragment of proBNP;
NT-proBNP, NH2-terminal fragment of proBNP; HF, heart failure; ECG,
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dedicated to evaluate in detail the diagnostic accuracy
and prognostic relevance of the assay of CNHs is not
available in the literature.
In June 2003, we performed a computerized literature
search on National Library of Medicine (i.e., PubMed
access to MEDLINE citations, at http://www3.ncbi.nlm.
nih.gov/PubMed/), using as the keywords “ANP” and
“BNP”, and found more than 12 300 and 1200 articles,
respectively. A more refined search with the keywords
“ANP or BNP assay” extracted 7000 and 800 articles,
respectively. Only studies specifically designed to evalu-
ate the diagnostic accuracy and prognostic relevance of
CNH measurements were selected from this huge mass of
articles to be discussed in this review.
Contrary to other recent reviews (1–7), we will analyze
in detail and critically compare the relevance of interrela-
tionships among the analytical performances of CNH
immunoassays, the population selection protocol, and the
“gold standard” used in the different studies. Moreover,
the diagnostic accuracy and prognostic relevance of as-
says of different CNHs in the entire spectrum of cardio-
vascular disease will be evaluated, whereas other reviews
have focused the discussion on one peptide only (mainly
BNP) and/or on one clinical condition only (mainly HF)
(2, 3, 5, 6). Finally, we will evaluate the clinical relevance
and cost-effectiveness of different CNH assays in all
clinical settings, including their use as screening methods
in asymptomatic individuals as well as their use as
diagnostic tests in primary care, emergency department,
coronary care unit, and cardiologic ambulatory and hos-
pital care settings.
Pathophysiologic Relevance of the CNH System
The CNHs include atrial natriuretic peptide (ANP), BNP,
and their related peptides, whereas C-type natriuretic
peptide and urodilatin, structurally related to the ANP/
BNP peptide family, are predominantly secreted by non-
cardiac tissues (endothelium and kidney, respectively)
(1–4, 6, 7 ). Recently, another peptide, called dendroaspis
natriuretic peptide, with a structure and biological activ-
ities similar to those of the CNH family, was identified,
but it is still uncertain whether dendroaspis natriuretic
peptide is an endogenous entity in humans (15 ).
CNHs have several physiologic actions, the most im-
portant being (a) vasodilation and a hypotensive effect; (b)
promotion of natriuresis and diuresis; (c) inhibition of the
sympathetic nervous system and of the activities of sev-
eral hormone systems, including the renin-angiotensin-
aldosterone system, endothelins, cytokines, and vasopres-
sin; (d) inhibition of the pathophysiologic mechanisms
responsible for ventricular and vascular hypertrophy and
remodeling; and (e) beneficial effects on endothelial dys-
function secondary to the atherosclerotic process, includ-
ing blunting of shear stress and regulation of coagulation
and fibrinolysis, as well as inhibition of platelet activation
(1–4, 6, 7 ).
CNHs are greatly increased in diseases characterized
by an expanded fluid volume, including renal failure,
liver cirrhosis, and HF (1 ). Table 1 lists the different
common clinical conditions affecting the circulating con-
centrations of CNHs.
An important pathophysiologic mechanism in cardio-
vascular disease is the imbalance between the vasocon-
strictive/antinatriuretic action of some neuroendocrine
factors, including the renin-angiotensin-aldosterone sys-
tem, vasopressin, endothelins, and sympathetic nervous
system, and the counterregulatory vasodilatory/natri-
uretic response, mainly represented by CNHs (6, 16). As
cardiac performance decreases, all neurohormonal sys-
tems are progressively stimulated in an attempt to sustain
cardiac output and circulatory homeostasis. However, the
activation of neurohumoral mechanisms may worsen the
hemodynamics, have direct adverse effects on myocardial
function, and stimulate the CNH system (16 ). According
to this hypothesis, the large increases in circulating con-
centrations of CNHs in HF could even be related to
activation of the neuroendocrine system and thus be
considered an adaptive and potentially protective re-
sponse mechanism in cardiovascular disease.
Concentrations of Circulating CNHs: Physiologic
Considerations and Clinical Interpretation
influence of age and gender
The circulating concentrations of CNHs are regulated or
modified by several physiologic factors, such as circadian
variations, age, gender, exercise, body posture, and water
immersion; eating habits, especially sodium intake; clini-
cal conditions (Table 1); and drugs, including corticoste-
roids, sex steroid hormones, thyroid hormones, diuretics,
angiotensin-converting enzyme (ACE) inhibitors, and ad-
renergic agonists and antagonists (1, 6).
Table 1. Diseases characterized by altered plasma cardiac
natriuretic peptides compared with healthy individuals.
Diseases CNH concentrations
Cardiac diseases
Heart failure Greatly increased
AMI (first 2–5 days) Greatly increased
Essential hypertension with LVHa Increased
Pulmonary diseases
Acute dyspnea Increased
Pulmonary embolism Increased
Obstructive pulmonary disease Increased
Endocrine and metabolic diseases
Hyperthyroidism Increased
Hypothyroidism Decreased
Cushing syndrome Increased
Primary hyperaldosteronism Increased
Diabetes mellitus Normal or increased
Liver cirrhosis with ascites Increased
Renal failure (acute or chronic) Greatly increased
Paraneoplastic syndrome Normal or increased
Subarachnoid hemorrhage Increased
a LVH, left ventricular hypertrophy.
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The wide variations in circulating concentrations of
CNHs in healthy adults in relation to aging and gender
could have particular clinical relevance (8, 17–19) (Fig. 1
and Table 2). Indeed, Vasan et al. (8 ) recently demon-
strated that the diagnostic accuracy of CNH assays for
community screening is gender dependent.
To explain these variations, the possible influence of
sex steroid hormones on the CNH system, as well as the
modification of the cardiovascular system with aging,
should be taken into account (20–23). According to these
mechanisms, the higher CNH values in women during
the fertile adult period could be explained by the physi-
ologic stimulation of female sex steroid hormones. In
particular, the BNP concentration is, on average, 36%
higher in women than in men at age50 years (Fig. 1 and
Table 2). The increases in CNHs with aging may be
attributable to the paraphysiologic decrease in myocardial
function and other organs, including the kidney, that is
typical of senescence (24 ). In this case, CNH assays may
be considered as biochemical markers of increased risk of
cardiac morbidity in old age (25 ). Moreover, the increase
in CNHs with aging may be attributable to a decrease in
their clearance rate. Indeed, an age modulation of maxi-
mum binding capacity of clearance (C-type) receptors for
CNHs was reported in platelets of elderly persons (26 ).
comparison between cnh assays and assays for
cnh-related prohormone peptides
All CNHs derive from preprohormones (i.e., preproANP
and preproBNP) containing a signal peptide sequence at
the NH2-terminal end. The prohormones (i.e., proANP
and proBNP) are produced by cleavage of signal peptide
and then are further split into inactive longer NH2-
terminal fragments (i.e., NT-proANP or NT-proBNP) and
a biologically active shorter COOH-terminal peptide (i.e.,
ANP or BNP), which are secreted in the blood in equimo-
lar amounts. However, ANP and BNP have shorter
plasma half-lives and, consequently, lower plasma con-
centrations than NT-proANP and NT-proBNP (Table 3)
(1, 6, 21).
Fig. 1. Mean (SE) circulating concentrations of BNP measured in 292
healthy individuals according to gender and five age groups.
The number of individuals included in each age group is indicated in parenthe-
ses. The characteristics of the population studied were reported in detail
elsewhere (17). (e, women; f, men.)
Table 2. Mean (SD) plasma BNP concentrations in 292
healthy individuals divided into groups according to gender
and age.a
Age Men Women Pb
20–50 years 5.9 (6.0) ng/L
(n  79)
10.0 (8.3) ng/L
(n  91)
0.0001
50 years 10.1 (7.8) ng/L
(n  53)
15.6 (11.8) ng/L
(n  68)
0.0033
Pb 0.0009 0.0020
a Individuals are the same reported in Fig. 1. The age cutoff of 50 years was
chosen because it corresponds to the mean age of menopause in Western
European countries. The number of individuals included in each subset is
indicated in parentheses. The characteristics of the population studied are
reported in detail elsewhere (17).
b Unpaired t-test using the logarithmic transformation of the original set of
data.
Table 3. Mean analytical sensitivity, mean (SD) values, and
ranges (minimum and maximum) of some commercial
competitive (EIA) and noncompetitive (IRMA, ELISA, and
ECLIA) immunoassays for CNH, used in our laboratory.a
Methodb
Analytical
sensitivity, pmol/L
Mean (SD),
pmol/L
Range,
pmol/L
IRMA ANP 0.73 5.6 (3.6) 0.2–16.6
IRMA BNP 0.75 2.9 (2.7) 0.1–12.4
TRIAGE BNP 1.44 2.9 (3.8) 0–14.2
ELISA proANP 76.9 731 (628) 43–1502
IRMA proANP 40.5 228 (99) 63–422
EIA proANP1–30 9.5 708 (251) 44–1289
EIA proANP31–67 38.4 1422 (790) 193–3339
EIA NT-proBNP8–29 13.6 246.8 (120.1) 64–488
EIA NT-proBNP32–57 4.0 117.5 (100.3) 0.2–368
ECLIA NT-proBNP 0.6 6.1 (4.1) 1.7–21.1
a The characteristics of the “normal” population studied have been reported in
detail elsewhere (17).
b IRMA ANP (SHIONOGI & Co., Ltd,.); IRMA BNP (SHIONOGI & Co., Ltd.);
TRIAGE BNP (BIOSITE); ELISA proANP (BIOMEDICA GRUPPE); IRMA proANP
(SHIONOGI & Co., Ltd.); EIA proANP 1–30 (BIOMEDICA GRUPPE); EIA proANP
31–67 (BIOMEDICA GRUPPE); EIA NT-proBNP8–29 (code BI-20852; BIOMEDICA
GRUPPE), uses an antiserum against the NH2-terminal proBNP8–29 peptide
fragment; EIA NT-proBNP32–57 (code BI-20862; BIOMEDICA GRUPPE), uses an
antiserum against the NH2-terminal proBNP32–57 peptide fragment; ECLIA NT-
proBNP (proBNP Elecsys System 2010; Roche Diagnostics).
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Studies on structure–activity relationships have shown
the importance of the central ring structure of CNHs,
formed by a disulfide bridge between the two cysteine
residues, for the binding to the specific receptors. For this
reason, only ANP and BNP, which present the disulfide
bridge in the peptide chain, share the typical hormonal
activity of CNHs, whereas NT-proANP and NT-proBNP
do not (1, 6, 21).
Theoretically, setting up an immunoassay for NT-
proANP and NT-proBNP should be easier because their
plasma concentrations are higher than those of ANP and
BNP (Table 3) (27 ). On the other hand, NT-proANP and
NT-proBNP immunoassays may be affected by several
analytical problems, mainly concerning different assay
specificities; consequently, very different results are pro-
duced by different methods (Table 3) (27 ). The different
analytical performances might affect the diagnostic accu-
racy of the assays for differentiating between individuals
with or without cardiac disease (27–29).
The respective advantages of assaying for the biologi-
cally active peptide hormones (ANP and BNP) and assay-
ing for NT-proANP and NT-proBNP are summarized in
Table 4. The inactive propeptides better fit the definition
of a disease marker than do circulating concentrations of
ANP or BNP, which on the other hand may be considered
a more reliable index of the activation (hormone) status of
the CNH system.
Taking into account the biochemical and physiologic
characteristics of the different peptides, it is conceivable
that ANP is a better marker of acute overload and/or
rapid cardiovascular hemodynamic changes than BNP or,
especially, than NT-proANP or NT-proBNP (1, 6, 27). For
example, circulating concentrations of ANP are known to
be more affected by body position and decreased to a
higher extent by a hemodialysis session in patients with
chronic renal failure than those of BNP, whereas plasma
NT-proANP is unchanged (1, 6, 27). Furthermore, ANP
increases more than NT-proANP during rapid ventricular
pacing (30 ).
Clinical Relevance of CNH Assays
The pathophysiologic and clinical relevance of CNH
assays has undergone a great deal of experimental and
clinical study, as reviewed recently (1–7, 31–34). In par-
ticular, it has been suggested that CNH assays may be
clinically useful (1–7, 31–38) for the screening and classi-
fication of patients with HF, as prognostic markers in
cardiac disease, for the follow-up of patients with HF, and
to avoid or reduce the need for expensive and/or unnec-
essary investigations. In the following paragraphs, we
will discuss in detail the use of CNH assays in these four
settings, taking into account both the pathophysiologic
considerations reported above and the findings of some
recent large observational studies or clinical trials, accord-
ing to evidence-based laboratory medicine principles (39–
42).
use of cnh assays in the screening and
classification of patients with cardiac
dysfunction
The diagnosis of HF can often be difficult, mainly in
primary care settings, where patients may present with
nonspecific symptoms and signs, such as dyspnea, fa-
tigue, and ankle swelling (5, 7, 14, 33, 43). In several pop-
ulation-based studies, 40% of patients with a suspected
diagnosis of HF in primary care had this diagnosis
confirmed by more specific and accurate clinical investi-
gations, which are often expensive, time-consuming, and
demanding for the patient (33, 43–45). As a result, a
relatively simple and inexpensive biochemical test (such
as a CNH assay) may be very useful to confirm the clinical
suspicion of HF in this clinical setting (5, 14).
diagnostic accuracy of cnh assays in
asymptomatic, mild ventricular systolic
dysfunction
Patients with asymptomatic left ventricular systolic dys-
function are likely to have lower plasma BNP than
patients with overt HF (1–7, 33, 46–50), as shown in Fig. 2.
Two recent studies (8, 9) evaluated the diagnostic
accuracy of the CNH assay as a screening method in a
general population. The first study analyzed the Framing-
ham Heart Study cohort (3177 individuals), using BNP
and NT-proANP in the evaluation of left ventricular
hypertrophy and systolic dysfunction in a community
population (8 ). Disease presence was evaluated by echo-
cardiographic findings (the prevalence of left ventricular
systolic dysfunction was 9.3% in the 1470 men and 2.5% in
1707 women tested, respectively). The area under the
ROC curve (AUC) for the ability of the CNH assay to
identify both left ventricular hypertrophy and systolic
dysfunction was, on average, 0.75, with a good specific-
ity (i.e., mean of 95% both in men and women) and
negative predictive value (NPV; mean of 92% and 93% in
men; 91% and 98% in women), but a poor sensitivity
(mean of 27% and 28% in men; 13% and 14% in women)
and positive predictive value (PPV; mean of 38% in men;
32% and 30% in women), based on use of gender-related
BNP cutoff values (8 ).
The aim of the second study was to examine the
validity of plasma BNP measurements (with the same
IRMA method as the other study) for detection of various
cardiac abnormalities in a rural Japanese population (1098
individuals; 693 men and 405 women) with a low preva-
Table 4. Relative advantages of ANP/BNP and
NT-proANP/BNP assays.
ANP/BNP NT-proANP/BNP
Close correlation between hormonal
and immunologic activities
Higher and more stable
circulating concentrations
Better correlation with physiologic or
clinical conditions after acute
changes of hemodynamics
Less degradation in vivo
and in vitro
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lence of coronary heart disease and left ventricular sys-
tolic dysfunction [i.e., only 37 participants (3.0%), showed
an ejection fraction (EF) 30%] (9 ). The diagnosis was
made by two independent cardiologists based on a med-
ical questionnaire, chest radiogram, ECG, and echocardio-
graphic report. The optimal threshold for identification of
disease was a BNP of 50 ng/L (14.4 pmol/L),2 with an
AUC for the ROC curve of 0.970, a sensitivity of 89.7%, a
specificity of 95.7%, a PPV of 44.3%, and a NPV of 99.6%.
The conclusions of these two studies, although similar
in aim as well as in clinical and experimental protocols,
were strongly conflicting. The Japanese study suggested
that the BNP assay is a very efficient and cost-effective
mass screening technique for identifying patients with
various cardiac abnormalities regardless of etiology and
degree of left ventricular systolic dysfunction (9 ), whereas
the Framingham study suggested only limited usefulness
of CNH assays as mass screening tools for this clinical
condition, especially in women (8 ).
These two studies, taken as a whole, indicate that CNH
assays may have only limited usefulness as screening
methods for HF in a general population because of the
poor sensitivity and PPV. However, both studies also
found good specificity and NPV, thus suggesting that
CNH assays may be used to rule out HF in an asymp-
tomatic (or paucisymptomatic) individual.
diagnostic accuracy of cnh assays in patients
with suspected hf
Some recent studies (33, 37, 38, 51–60) reported that CNH
assays could be useful as screening methods and/or for
the differential diagnosis of patients suspected of HF in
the following clinical settings: (a) randomly selected gen-
eral (low-risk) and/or high-risk community populations
(37, 51, 54); (b) patients with a primary care new diagnosis
of HF (52 ); (c) patients with acute dyspnea in the emer-
gency department (55, 57); (d) consecutive unselected
hospital inpatients (53, 56, 58); and (e) patients admitted
to the intensive care unit (59, 60). The main characteristics
of study protocols and the diagnostic accuracy of the best
designed studies are reported in Table 5.
Abnormalities of diastolic function may play a major
role in determining signs and symptoms of congestive HF
(33, 61, 62). Although Doppler echocardiography is cur-
rently used to examine left ventricular diastolic filling
dynamics, the limitations of this technique suggest the
need for other objective measures (63 ). Some studies
suggest that CNH assays, in particular a BNP assay, may
be useful for the diagnosis of left ventricular diastolic
dysfunction (11, 64, 65), although the authors of a small
study (34 patients) found no significant correlation be-
tween a CNH assay and decreased diastolic function
attributable to doxorubicin-induced cardiotoxicity in chil-
dren with cancer (66 ). The reason for some conflicting
results may be the different causes and/or mechanisms
responsible of cardiac dysfunction (67 ).
diagnostic accuracy of cnh assays in patients
with acute myocardial infarction
Circulating concentrations of CNHs increase after acute
myocardial infarction (AMI); the extent of the increase is
related to the size of the infarct (68–71). Patients with
smaller infarcts tend to have a monophasic increase in
plasma BNP, peaking at 20 h after the onset of symptoms;
on the other hand, those with larger infarcts, lower EF,
and clinical signs of HF may present an additional peak at
5 days after admission (69 ).
Some studies are less convincing regarding the ability
of CNH assays to identify patients with significant ven-
tricular damage after AMI (72, 73). These conflicting
results could be attributable to the differences in sample
collection time, type of CNH (ANP, BNP, or NT-proBNP)
measured, type of assay (competitive vs noncompetitive),
and inclusion criteria adopted. In summary, CNH assays
2 Conversion factors: In this review, both conventional (ng/L) and SI
(pmol/L) units have been reported. The text first reports the units as originally
used in a cited article (in ng/L or pmol/L) and then gives the corresponding
calculated units after conversion. It is important to note that the conversion
from the conventional to SI units (or vice versa) for NT-proANP and
NT-proBNP may present some drawbacks because the immunoassays use
different materials as calibrators to generate the calibration curves.
Fig. 2. Circulating concentrations of ANP and BNP measured in healthy
individuals and in patients with HF, divided according to severity of
disease.
, controls; 1, mild HF (patients in NYHA classes I and II); o, severe HF
(patients in NYHA classes III and IV). The number of individuals included in each
group is indicated in parentheses. The results are expressed as box-and-whisker
plots with the lines inside the boxes indicating the median (50th percentile), the
limits of the boxes indicating the 25th and 75th percentiles, and the whiskers
indicating the 10th and 90th percentiles. All values above the 90th percentile
and below the 10th percentile (outliers) are plotted separately (as F). Data are
from Refs. (48–50).
Clinical Chemistry 50, No. 1, 2004 37
Ta
bl
e
5
.
S
tu
dy
pr
ot
oc
ol
s
an
d
di
ag
no
st
ic
ac
cu
ra
cy
of
C
N
H
as
sa
y
in
pa
ti
en
ts
w
it
h
H
F.
A
ut
ho
rs
,
ye
ar
(R
ef
.)
S
tu
dy
pr
ot
oc
ol
C
N
H
,
cu
to
ff
va
lu
e
(a
ss
ay
)
R
O
C
(9
5
%
C
I)
S
en
si
ti
vi
ty
,
%
S
pe
ci
fic
it
y,
%
P
P
V
,
%
N
P
V
,
%
O
m
la
nd
et
al
.,
1
9
9
6
(5
1
)
C
on
se
cu
tiv
e
se
rie
s
of
2
5
4
pa
tie
nt
s
un
de
rg
oi
ng
le
ft
ca
rd
ia
c
ca
th
et
er
iz
at
io
n
w
er
e
en
ro
lle
d
in
th
e
st
ud
y;
1
2
8
w
ith
a
hi
st
or
y
of
pr
ev
io
us
AM
I
AN
P
(R
IA
)
0
.6
6
5
N
T-
pr
oA
N
P
(R
IA
)
0
.6
1
0
B
N
P
(R
IA
)
0
.7
8
9
C
ow
ie
et
al
.,
1
9
9
7
(5
2
)
1
2
2
co
ns
ec
ut
iv
e
pa
tie
nt
s
re
fe
rr
ed
to
a
ra
pi
d-
ac
ce
ss
H
F
cl
in
ic
w
ith
a
ne
w
pr
im
ar
y
ca
re
di
ag
no
si
s
of
H
F
AN
P
(R
IA
)
0
.9
3
9
7
7
2
5
5
9
8
N
T-
pr
oA
N
P
(R
IA
)
0
.8
9
9
7
6
6
5
4
9
8
B
N
P
(R
IA
)
0
.9
6
9
7
8
4
7
0
9
8
R
ic
ha
rd
s
et
al
.,
1
9
9
8
(6
0
)
C
on
se
cu
tiv
e
se
rie
s
of
1
2
1
pa
tie
nt
s
ad
m
itt
ed
to
th
e
co
ro
na
ry
ca
re
un
it
w
ith
AM
I
N
T-
pr
oB
N
P,
1
6
0
pm
ol
/L
(1
3
5
3
ng
/L
;
R
IA
)
9
1
7
2
3
9
9
7
H
ob
bs
et
al
.,
2
0
0
2
(5
4
)
5
9
1
pa
tie
nt
s
w
er
e
en
ro
lle
d,
st
ra
tif
ie
d
fo
r
ag
e
an
d
so
ci
oe
co
no
m
ic
st
at
us
,
an
d
di
vi
de
d
in
to
fo
ur
co
ho
rt
s
(g
en
er
al
po
pu
la
tio
n,
pa
tie
nt
s
w
ith
an
ex
is
tin
g
cl
in
ic
al
la
be
lo
f
H
F,
pa
tie
nt
s
on
di
ur
et
ic
s,
an
d
pa
tie
nt
s
de
em
ed
at
ris
k
of
H
F)
N
T-
pr
oB
N
P,
3
6
pm
ol
/L
(3
0
4
ng
/L
;
EL
IS
A)
0
.9
2
(0
.8
2
–1
.0
)a
0
.8
(0
.7
2
–0
.8
8
)b
1
0
0
a
1
0
0
b
7
0
a
1
8
b
7
a
3
b
1
0
0
a
1
0
0
b
M
ai
se
le
t
al
.,
2
0
0
2
(5
5
)
1
5
8
6
pa
tie
nt
s
w
ho
ca
m
e
to
th
e
em
er
ge
nc
y
de
pa
rt
m
en
ts
of
se
ve
n
di
ff
er
en
t
si
te
s
w
ith
ac
ut
e
dy
sp
ne
a
B
N
P,
1
0
0
ng
/L
(2
8
.9
pm
ol
/L
;
IL
M
Ac
PO
C
T)
0
.9
1
(0
.9
0
–0
.9
3
)
9
0
7
6
Ap
pl
e
et
al
.,
2
0
0
3
(5
6
)
3
3
4
pa
tie
nt
s
ru
le
d
in
or
ou
t
fo
r
co
ng
es
tiv
e
H
F
or
be
in
g
m
on
ito
re
d
fo
r
H
F
th
er
ap
y
de
ci
si
on
fo
r
a
pe
rio
d
of
8
m
on
th
s
in
tw
o
ur
ba
n
te
ac
hi
ng
ho
sp
ita
ls
B
N
P,
1
0
0
ng
/L
(2
8
.9
pm
ol
/L
;
IL
M
A
PO
C
T)
0
.9
1
5
9
4
.8
7
7
.1
8
5
.3
9
1
.4
B
ay
et
al
.,
2
0
0
3
(5
8
)
D
ur
in
g
a
1
0
-m
on
th
pe
rio
d,
2
1
9
3
pa
tie
nt
s
ad
m
itt
ed
to
a
ci
ty
ge
ne
ra
lh
os
pi
ta
l(
8
0
%
of
ta
rg
et
ed
pa
tie
nt
s)
w
er
e
en
ro
lle
d
N
T-
pr
oB
N
P,
3
5
7
pm
ol
/L
(3
0
1
9
ng
/L
;
EL
IS
A)
0
.8
5
7
3
8
2
2
4
9
8
M
ai
se
le
t
al
.,
2
0
0
3
(5
7
)
4
5
2
pa
tie
nt
s
w
ith
a
fin
al
ad
ju
di
ca
te
d
di
ag
no
si
s
of
co
ng
es
tiv
e
H
F
w
ho
un
de
rw
en
t
ec
ho
ca
rd
io
gr
ap
hy
w
ith
in
3
0
da
ys
of
th
ei
r
vi
si
t
to
th
e
em
er
ge
nc
y
de
pa
rt
m
en
t
B
N
P,
1
0
0
ng
/L
(2
8
.9
pm
ol
/L
;
IL
M
A
PO
C
T)
0
.9
0
(0
.8
8
–0
.9
1
)
9
0
7
3
7
5
9
0
N
ie
ls
en
et
al
.,
2
0
0
3
(3
7
)
A
ra
nd
om
sa
m
pl
e
of
1
2
5
7
co
m
m
un
ity
m
em
be
rs
w
as
ex
am
in
ed
as
a
pr
e-
ec
ho
ca
rd
io
gr
ap
hi
c
sc
re
en
in
g
te
st
fo
r
le
ft
ve
nt
ric
ul
ar
sy
st
ol
ic
dy
sf
un
ct
io
n
B
N
P,
8
ng
/L
(0
.9
pm
ol
/L
;
R
IA
)
0
.8
6
9
2
5
3
7
9
9
.4
a
G
en
er
al
po
pu
la
tio
n

4
5
ye
ar
s
of
ag
e
(n

3
0
7
).
b
Pa
tie
nt
s
w
ith
ex
is
tin
g
di
ag
no
si
s
of
H
F
(n

1
3
3
).
c
IL
M
A,
im
m
un
ol
um
in
om
et
ric
as
sa
y.
38 Clerico and Emdin: Diagnostic Accuracy of Cardiac Natriuretic Peptides
seem to be only moderately useful in assessing left
ventricular dysfunction after AMI. However, persisting
increases in CNHs at 1 or 2 months after AMI would
suggest a high risk of adverse remodeling and subsequent
HF, although this finding should be confirmed by addi-
tional well-designed studies.
diagnostic accuracy of cnh assays in the
elderly
HF is primarily a disease of old age. The authors of some
recent studies have reported that BNP assays could be
clinically useful in elderly people suspected to have HF
(25, 36). In particular, a prospective cohort study specifi-
cally evaluated the diagnostic accuracy for HF of BNP
assays in 299 consecutive patients (mean age, 79 years;
65% women) attending a day-hospital over a period of 13
months (36 ). This study suggested that both BNP assays
and ECG were sensitive in detecting left ventricular
systolic dysfunction but lacked specificity (the combina-
tion of the two tests improved diagnostic accuracy) and
that BNP concentrations increased progressively as the
number of different cardiac abnormalities increased (36 ).
diagnostic accuracy of cnh assays in other
clinical conditions
CNH assays could be clinically useful in other clinical
conditions. For example, a very recent study (74 ) reported
that NT-proBNP [measured by an electrochemilumines-
cent assay (ECLIA)] was the most sensitive index of
myocardial dysfunction and the most powerful prognos-
tic determinant in primary systemic amyloidosis. Further-
more, this assay can add prognostic information for
newly diagnosed patients more effectively than echocar-
diography and can be useful in designing therapeutic
strategies and monitoring response (74 ).
Another example is the possibility, mainly by BNP
assay, of identifying HF related to anthracycline cardio-
toxicity (66, 75–78).
comparison of cnh assays with other markers
of hf
Signs and symptoms correlate poorly with the presence of
HF (5, 33, 79). Davie et al. (80 ) found that left ventricular
systolic dysfunction was virtually never present if the
ECG was normal (sensitivity, 94%; NPV, 98%), and a
screening ECG reduced the need of echocardiograms by
50%.
However, CNH measurements may exclude a normal
heart with high probability, reducing the echocardio-
graphic diagnostic burden (31, 33, 37, 79). Choy et al. (81 )
showed that in post-AMI patients, plasma BNP is supe-
rior to all clinical indices of left ventricular systolic
dysfunction (EF 40%), including signs and symptoms
and a clinical score (Peel Index). Talwar et al. (82 )
examined the value of NT-proBNP (measured by a com-
petitive immunoluminometric assay), abnormal ECG, and
other baseline clinical and laboratory variables in identi-
fying patients with left ventricular systolic dysfunction in
a high-risk population (243 patients; 129 men; median
age, 73 years; range, 20–94 years). NT-proBNP alone was
a better predictor of left ventricular dysfunction than any
other single or combination of factors, whereas the ECG
had a poor predictive value for left ventricular systolic
dysfunction (82 ). Cowie et al. (52 ) (Table 5) reported that
ROC curves for BNP (AUC, 0.96), ANP (0.93), and NT-
proANP (0.89) were better than that of cardiothoracic
ratio on chest radiogram (0.79) in screening for patients
likely to have HF and requiring further clinical assess-
ment. Nielsen et al. (37 ) (Table 5) found that BNP assay, at
a cutoff 8 ng/L (0.9 pmol/L), showed a diagnostic
accuracy better than that of ECG (sensitivity, 57%; speci-
ficity, 85%; PPV, 13%; NPV, 98%) in a random sample of
1257 individuals in a community.
It may well be that a combination of tests is the optimal
approach for screening patients with suspected HF (60 ).
Indeed, Richards et al. (60 ) showed that a combination of
NT-proBNP RIA and echocardiographic evaluation of left
ventricular function better defined the risk of mortality
and/or HF in patients with AMI than either test alone. In
particular, for prediction of death over 24 months of
follow-up, an early postinfarction NT-proBNP concentra-
tion 160 pmol/L (1353 ng/L) had a prognostic accuracy
superior to any other neurohormone measured and to
assessment of left ventricular EF by echocardiography
(Table 5). By multivariate analysis, NT-proBNP provided
predictive information for left ventricular failure and
death, independently from age, gender, left ventricular
EF, concentrations of other hormones, previous history of
HF, myocardial infarction, hypertension, or diabetes (60 ).
Use of CNHs as Prognostic Markers
The authors of several well-designed and conducted
studies suggested that CNHs may be useful as prognostic
markers mainly in two clinical conditions: HF and acute
coronary artery syndromes (ACS), as reviewed recently
(1–7, 33, 38, 79, 83–86).
prognosis in hf
The main protocol characteristics and results of some
studies (87–91) that evaluated the prognostic value of
CNH assays in patients with HF are reported in Table 6.
In all of these studies, BNP and NT-proBNP (but not ANP
and NT-proANP) were always found to be independent
risk markers for morbidity and/or mortality (87–89).
Two studies specifically investigated whether CNH
assays can predict mortality in elderly persons (25, 92).
Wallen et al. (92 ) studied the relationship of BNP concen-
trations with aging and whether BNP could reflect current
disease states in the general elderly population (545
individuals 85 years of age). In multivariate analysis,
BNP concentrations were predictive of ischemic heart
disease, atrial fibrillation, renal dysfunction, congestive
HF, and treatment with -adrenergic blockers (92 ).
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Ueda et al. (25 ) investigated the prognostic implica-
tions and potential causes of the increased concentrations
of BNP (measured by IRMA) in 111 individuals (age 80
years) who had no history of hospitalization for cardiac
disease. During a 24-month follow-up, 8 individuals (7%)
were hospitalized with cardiac disorders and 21 (19%)
died. Each 50-ng/L (14.4 pmol/L) increase in the plasma
BNP concentration was associated with a 1.6-fold [95%
confidence interval (CI), 1.2- to 2.1-fold] increase in the
risk of cardiac events and a 1.4-fold (95% CI, 1.2- to
1.6-fold) increase in total mortality.
prognosis in acs
ACS encompasses a continuum of cardiac ischemic events
ranging from unstable angina pectoris with no biochem-
ical evidence of myocardial necrosis to ST-elevation AMI
(93, 94). The prognosis for patients with ACS varies
widely, and several clinical, ECG, and biochemical mark-
ers have been used to identify high-risk individuals in
need of aggressive intervention (93–95).
Recently, CNH assays (in particular for BNP and
NT-proBNP) have been shown to provide valuable prog-
nostic information for patients with ACS (33–35, 60, 72, 86,
95–107). A summary of study protocol characteristics and
mean results of the best-designed studies are reported in
Table 7.
prognostic relevance of cnh assays in the
general population
Some studies have evaluated the prognostic relevance of
CNH assays in the general population, especially the
elderly (25, 92, 99, 108–110). The studies by Ueda et al.
(25 ) and McDonagh et al. (99 ) (Table 7) have been
discussed previously.
Davis et al. (108) studied 331 elderly volunteers free of
acute illness at study entry [mean (SD) age, 88 (7) years;
23% men] in a 1-year prospective blinded cohort study.
The risk of overt HF increased progressively with increas-
ing ANP. In multivariate analysis, only two independent
variables significantly predicted acute congestive HF dur-
ing the 1-year follow-up period: ANP 200 pmol/L (615
ng/L; adjusted odds ratio, 7.9; 95% CI, 3.2–19.2] and a
history of HF in the previous year (adjusted odds ratio,
7.0; 95% CI, 2.9–17).
Wallen et al. (92, 109) studied whether prospective
measurements of circulating concentrations of ANP, NT-
proANP, and BNP could predict mortality in a cohort of
85-year-old individuals from the general population (n 
541), who were followed up prospectively for 5 years.
Plasma BNP predicted 5-year mortality better than ANP
and NT-proANP in the total population as well as in
individuals without a defined cardiovascular disorder
(92, 109).
It can be hypothesized that hypertension-prone indi-
viduals may have increased CNH concentrations as a
result of increased ventricular wall stress or vascular
stiffness early in the course of the disease. If this hypoth-
esis is true, CNH assays could serve as markers of future
hypertension risk in the general population. Freitag et al.
(110) evaluated the relationship of plasma BNP (mea-
sured by IRMA) with longitudinal blood pressure track-
ing and incidence of hypertension in 1801 nonhyperten-
sive Framingham Heart Study participants (mean age, 56
years; 57% women). In multivariate models adjusting for
known risk factors, increased plasma BNP was associated
with increased risk of blood pressure progression in men
(odds ratio of 1.15 for trend across categories; P  0.046)
but not in women (P  0.82).
Table 6. CNH assays as prognostic risk markers in patients with HF.
Authors, year
(Ref.) Study protocol
CNH assay
(method) Main results
Benedict et al.,
1996 (87)
A subset of 241 patients with asymptomatic left
ventricular dysfunction were enrolled in the
SOLVD Prevention Trial
ANP (RIA) Risk ratio, 0.8 (0.38–1.65) for all clinical
events (P  0.54)
Tsutamoto et al.,
1999 (88)
290 consecutive patients with asymptomatic or
minimally and newly symptomatic left
ventricular dysfunction (functional classes I–II;
mean left ventricular EF, 37%) were studied
ANP (IRMA)
BNP (IRMA)
BNP risk ratio, 1.004 (1.003–1.006) for
2-year mortality (P 0.0001);
ANP, P  0.05.
Stanek et al.,
2001 (89)
91 patients with HF (left ventricular EF 25%)
receiving 40 mg/day enalapril and double-
blind atenolol (50–100 mg/day) or placebo
were enrolled
NT-proANP (ELISA)
NT-proBNP (ELISA)
BNP (RIA)
BNP (P  0.0001) and NT-proBNP (P 
0.0027) independently related to 4-year
mortality by multivariate Cox regression
analysis
Anand et al.,
2003 (90)
Plasma BNP was measured before
randomization and during follow-up in 4300
patients (the Valsartan HF Trial).
BNP (IRMA) Risk ratio, 2.1 (1.79–2.42) for mortality;
2.2 (1.98–2.52) for morbidity (P 
0.0001)
Koseki et al.,
2003 (91)
Multicenter (21 hospitals) prospective
observational approach: 721 patients were
recruited with chronic HF (the CHART study).
BNP (unspecified) Risk ratio, 1.90 (1.04–3.47) for DC,a 2.02
(1.01–4.04) for AMI; 1.70 (1.02–2.84)
for VHD; 2.68 (1.03–6.96) for LVH for
1-year incidence of all events, including
all deaths and HF hospitalization
a DC, dilated cardiomyopathy; VHD, valvular heart disease; LVH, left ventricular hypertrophy.
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prognostic relevance of cnh assays in
pulmonary diseases
The prognostic relevance of CNHs has been evaluated in
acute and/or chronic pulmonary diseases because it is
well known that circulating concentrations of CNHs in-
crease in these clinical conditions with the degree of
hypoxia and right heart overload (111–116).
Ishii et al. (113) evaluated whether plasma BNP
and ANP (measured by IRMA) were useful markers of
right ventricular overload and whether they had prog-
nostic value as predictors of death in 31 consecutive
patients with chronic respiratory disease who under-
went right-heart catheterization. During a follow-up pe-
riod 12 months, BNP (P 0.05) was an independent
Table 7. CNH assay as prognostic risk marker in patients with ACS
Authors, year (Ref.) Study protocol CNH assay (method) Mean results
Arakawa et al.,
1996 (96)
A cohort of 70 patients with AMI were enrolled.
Measurements were obtained on admission
(mean 6 h after onset) and on day 2 after onset.
Mean follow-up period was 18 months
ANP (RIA)
BNP (RIA)
BNP related to survival after AMI by Cox
proportional hazards model analysis
(P0.0001)
Darbar et al.,
1996 (97)
CNHs were measured in a cohort of 75 patients
after AMI, followed for on average 19.7 months
ANP (RIA)
BNP (RIA)
ANP identified patients at risk of symptomatic
HF (P0.002) and hospitalization
(P0.019). BNP was the only significant
independent predictor of cardiovascular
mortality (P0.0001)
Omland et al.,
1996 (72)
Venous blood samples for CNH assay were
obtained on day 3 after symptom onset from a
cohort of 131 patients with documented AMI,
followed for a median period of 1293 days
ANP (RIA)
NT-proANP (RIA)
BNP (IRMA)
BNP was an independent predictor of
cardiovascular mortality by multivariate Cox
regression analysis (P0.021), but not
ANP and NT-proANP
Crilley and Farrer,
2001 (98)
133 initial survivors of a first AMI who received
thrombolytic treatment were studied for a follow-
up period of 1 year
BNP (RIA) Baseline BNP was associated with 1-year
mortality by multiple linear regression
analysis (P0.003)
Richards et al.,
2001 (100)
NT-proBNP was assessed for prediction of adverse
outcome in a cohort of 297 patients with
ischemic left ventricular dysfunction who were
randomly assigned to receive carvedilol or
placebo
NT-proBNP (RIA) Risk ratio for mortality: 4.67 (2–10.9;
P0.001)
Risk ratio for hospital admission with HF:
4.7 (2.2–10.3; P0.001)
De Lemos et al.,
2001 (35)
BNP in plasma specimens obtained a mean (SD)
of 40 (20) h after the onset of ischemic
symptoms in 2525 patients from TIMI 16 study.
Baseline BNP values were correlated with the
risk of death, HF, and AMI at 30 days and 10
months
BNP (unspecified) Odds ratios for death at 10 months in the
second, third, and fourth quartiles of BNP
were 3.8 (1.1–13.3), 4.0 (1.2–13.7), and
5.8 (7–19.7). BNP was associated with the
risk of new or recurrent AMI and new or
worsening HF at 10 months
McDonagh et al.,
2001 (99)
A random sample of a cohort of 1640 men and
women 25–74 years of age, from a geographic
urban population, followed for 4 years was
enrolled
BNP (RIA)
NT-proBNP (RIA)
BNP (17.9 ng/L; 5.2 pmol/L) was an
independent predictor of 4-year all-cause
mortality by multivariate analysis
(P0.006)
Omland et al.,
2002 (95)
Blood samples for CNH assay were obtained in the
subacute phase in 204 patients with ST-
elevation AMI: 220 with non-ST segment
elevation AMI and 185 with unstable angina in
the subacute phase, followed for a median
follow-up of 51 months
NT-proBNP (ILMA) NT-proBNP was independent predictor of
mortality with a mean risk ratio of 2.4
(1.1–5.4)
Jernberg et al.,
2002 (104)
A cohort of 755 patients admitted because of
chest pain and no ST-segment elevation was
studied. Patients were followed concerning death
for 40 months (median)
NT-proBNP (ECLIA) Compared with the lowest quartile, patients
in the second, third, and fourth quartiles
had a relative risk of subsequent death of
4.2 (1.6–11.1), 10.7 (4.2–26.8), and 26.6
(10.8–65.5), respectively. NT-proBNP was
independently associated with prognosis by
a Cox regression model
Morrow et al.,
2003 (106)
A cohort of 1676 patients, with non-ST-elevation
ACSs, and randomized to early invasive versus
conservative management (TIMI study) was
studied
BNP (ILMA POCT) BNP was independent predictor of mortality at
6 months with a mean odds ratio of 3.3
(1.7–6.3). BNP 80 ng/L (23.1 pmol/L)
increased by fivefold the risk of developing
new congestive HF by 30 days (5.9% vs
1.0%; P0.0001)
Richards et al.,
2003 (107)
A cohort of 666 patients with AMI were studied
followed for 3 years
BNP (RIA)
NT-proBNP (RIA)
NT-proBNP was an independent predictor of
death 6.63 (3.72–11.79) by stepwise Cox
proportional hazrads regression analysis.
NT-proBNP and BNP were equivalent
prognostic markers for clinical outcomes
(P0.01)
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predictor of end-stage chronic respiratory disease death
(113).
Nagaya et al. (114) sought to assess the prognostic
significance of plasma BNP (measured by IRMA) in 60
patients with primary pulmonary hypertension at diag-
nostic catheterization. Measurements were repeated in 53
patients after a mean follow-up period of 3 months.
During a mean follow-up period of 24 months, 18 patients
died of cardiopulmonary causes. According to multivar-
iate analysis, baseline plasma BNP was an independent
predictor of mortality. Survival was strikingly worse for
patients with a supramedian value of follow-up BNP
[180 ng/L (52 pmol/L)] than for those with an inframe-
dian value (P 0.0001). In addition, ROC analysis indi-
cated that the prognostic power of BNP was comparable
or even superior to that of hemodynamic evaluation
(114).
Another study (115), in which 110 consecutive patients
were evaluated, examined whether plasma BNP (mea-
sured by IRMA) is a predictor of fatal pulmonary embo-
lism. The relationship between BNP concentration mea-
sured at presentation and clinical outcome was assessed
by comparing the proportion of outcome events among
tertiles. The risk of death related to pulmonary embolism
if BNP was 21.7 pmol/L (75 ng/L) was 17% (95% CI,
6–33%). The NPV for uneventful outcome in individuals
with a BNP value 21.7 pmol/L (75 ng/L) was 99% (95%
CI, 93–100%) (115).
Kucher et al. (116) measured plasma BNP with a
point-of-care testing (POCT) method to determine its
prognostic value in 73 consecutive patients with acute
pulmonary embolism. A BNP cutoff of 90 ng/L (26
pmol/L) was used for the prediction of a major adverse
cardiovascular event. The sensitivity, specificity, NPV,
and PPV were 85% (95% CI, 64–95%), 75% (62–85%), 93%
(81–98%), and 57% (39–73%), respectively. Moreover, low
BNP [50 ng/L (14.4 pmol/L)] identified 95% of patients
with a benign clinical course of acute pulmonary embo-
lism (116).
diagnostic accuracy and prognostic relevance
of cnh assays in kidney diseases
It is well known that cardiovascular events are the major
prognostic determinants in patients with chronic hemo-
dialysis (cardiovascular deaths representing 50% of
total mortality). In these patients, creatinine concentra-
tions are associated with increased risk of mortality,
cardiovascular disease, and chronic HF (117, 118). Circu-
lating concentrations of CNHs are greatly increased in
renal failure, and several studies tested their diagnostic
accuracy and prognostic relevance (119–128).
Ishii et al. (124) prospectively compared the predictive
value of myocardial necrosis markers (cardiac troponin T
and I) and CNHs (ANP and BNP, both measured by
IRMA methods) in 100 consecutive outpatients on chronic
dialysis without ACS. In a stepwise multivariate Cox
regression analysis, only cardiac troponin T (P 0.05 and
P 0.01) and a history of HF requiring hospitalization (P
0.05 and P 0.005) were independent predictors of both
all-cause and cardiac mortality after a 2-year follow-up
(124). Cataliotti et al. (125) examined the relationship of
CNHs with cardiac mortality in 112 dialysis patients
without clinical evidence of congestive HF. BNP concen-
trations were significantly associated with greater risk of
cardiovascular death in a Cox regression analysis (P
0.001), as was the ANP concentration (P  0.002) (125).
Goto et al. (126) investigated whether increased plasma
concentrations of ANP or BNP predicted future cardiac
events in 53 patients undergoing chronic hemodialysis
without clinical symptoms suggestive of cardiac disorders
and followed for 11.3 (0.2) months. Using the Kaplan–
Meier method, Goto et al. (126) found that the incidence
of cardiac events was significantly greater in patients with
higher concentrations of ANP (50.0% vs 0.0%) or BNP
(72.7% vs 11.9%). Naganuma et al. (127) monitored car-
diac mortality for 36 months in 164 hemodialysis patients
and 14 healthy volunteers. By stepwise multivariate Cox
proportional hazards analysis, they found that BNP (rel-
ative risk ratios, 1.002; 95% CI, 1.001–1.002), left ventric-
ular mass index (1.027; 95% CI, 1.013–1.042) and C-reac-
tive protein (2.192; 95% CI, 1.532–3.135) were independent
predictors of cardiac death compared with other biochem-
ical and clinical markers (127).
The clinical relevance of CNH assay in the stratification
risk for cardiac or total mortality in patients with renal
failure is uncertain, as suggested by the conflicting results
reported above (119–128). The usefulness of CNH assays
as diagnostic markers of cardiac function in patients with
end-stage renal disease is also doubtful, especially when
taking into account the different behavior of CNHs and
their N-terminal propeptides and when comparing it with
other biomarkers and/or hemodynamic indices
(6, 27, 124, 128). Whereas only few data are available on
NT-proBNP assays, BNP assays seem to show better
diagnostic accuracy and clinical performance as prognos-
tic markers than ANP assays.
These conflicting results could be attributable to the
relatively small number of patients studied compared
with the larger number of patients in studies concerning
HF or ACS. Moreover, only studies with long follow-up
periods in a large population allow accurate determina-
tion of a sound number of clinically significant events
(40, 41). Furthermore, renal failure can be considered to
be the end-stage of all renal diseases, so that patients with
chronic renal failure studied by different groups could
have very different clinical histories and characteristics,
pharmacologic treatments, and cardiovascular risk back-
grounds. Whereas glomerulonephritis was the leading
cause of chronic renal failure in the past, diabetic and
hypertensive nephropathies are now more frequent (129).
Patients with diabetes mellitus and systemic arterial hy-
pertension are also at high risk for major cardiovascular
events; consequently, the prevalence of hypertension
and/or diabetes can greatly influence evaluations of the
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diagnostic accuracy and risk power for a CNH assay in
patients with renal failure.
CNH Assays in the Follow-Up of Patients with HF
Medical therapy for HF is based on improving the symp-
toms and signs of fluid retention (change in dyspnea,
edemas, and body weight are the usual markers of
response to treatment) and titrating the dosage of drugs
(such as diuretics, ACE inhibitors, -blockers, and spi-
ronolactone), according to the evidence from randomized
clinical trials (14, 33, 43). Currently, there is no specific
surrogate endpoint for treating patients with HF that can
be used to fine tune therapy (14, 33, 34, 43).
Several authors have suggested that CNH assays may
be useful in monitoring and tailoring the medical therapy
in patients with HF (5, 33, 34, 84, 90, 100, 130–135). To
provide a practical objective indicator of optimal anti-HF
therapy, CNHs should respond to drug treatment. In-
deed, ACE inhibitors, valsartan, diuretics, and nitrates
have been shown to reduce plasma CNH concentrations
in parallel with hemodynamic and clinical improvement
(34, 84, 130, 136–144). More variable effects on plasma
CNH concentrations have been reported after -blockade
and are at least in part attributable to their differing
specificities or to ancillary properties (34, 84, 90, 132, 137,
145–148). Acute administration of -blockers may pro-
vide an early increase in plasma CNHs, whereas sus-
tained treatment with associated improvement in cardiac
function and reduction in filling pressure and cardiac
volumes should be associated with a decrease in hormone
concentrations (34 ).
At present, only two published studies (130, 131) were
designed to specifically evaluate the clinical use of CNH
assays in monitoring and tailoring the medical therapy in
patients with HF.
Murdoch et al. (130) sought to determine whether
titration of vasodilator therapy according to plasma BNP
may be of value in the individual optimization of vasodi-
lator therapy in chronic HF. Twenty patients with mild to
moderate chronic HF and receiving stable conventional
therapy were randomly assigned to titration of the ACE
inhibitor dosage according to serial measurements of
plasma BNP or to optimal empiric ACE inhibitor therapy
for 8 weeks. Only the BNP-driven approach was associ-
ated with significant reductions in plasma BNP concen-
trations throughout the duration of the study and a
significantly greater suppression compared with empiric
therapy after 4 weeks [42.1% (95% CI, 58.2% to
19.7%) vs 12.0% (31.8% to 13.8%), P  0.03]. This
study suggests that plasma BNP may be chronically
reduced by tailored vasodilator therapy in patients with
chronic HF. Furthermore, titration of vasodilator therapy
according to plasma BNP was associated with more
profound inhibition of the renin-angiotensin-aldosterone
system and a significant decrease in heart rate compared
with empiric therapy (130).
Troughton et al. (131) hypothesized that pharmaco-
therapy guided by plasma concentrations of the NT-
proBNP would produce a superior outcome to empirical
trial-based treatment dictated by clinical acumen. In this
study, 69 patients with impaired systolic function (EF
40%) and symptomatic HF [New York Heart Associa-
tion (NYHA) class II–IV] were randomized to receive
treatment guided by either plasma NT-proBNP concen-
tration or standardized clinical assessment. During the
follow-up (minimum of 6 months; median, 9.5 months),
there were fewer total cardiovascular events (death, hos-
pital admission, or HF decompensation) in the NT-
proBNP-guided group than in the clinical group (19 vs 54;
P  0.02). At 6 months, 27% of patients in the NT-
proBNP-guided group and 53% in the clinical group had
experienced a first cardiovascular event (P  0.034).
Changes in left ventricular function, quality of life, renal
function, and adverse events were similar in both groups.
This study indicates that NT-proBNP-guided treatment of
HF reduced total cardiovascular events and delayed time
to first event compared with intensive clinically guided
treatment (131).
Can CNH Assays Reduce the Need for Cardiac
Investigations?
It has been suggested that CNH assays could reduce the
need for cardiac investigations (14, 31, 33). Indeed, ruling
out HF by use of CNH assays would make unnecessary
other investigations, which are often time-consuming,
expensive, invasive, and sometimes, potentially harmful
for the patient (14 ). However, at the present time, only
one published study was designed to test this possibility.
Nielsen et al. (37 ) sought to assess the cost-effectiveness of
using plasma BNP (measured by RIA) as a pre-echocar-
diographic screening test for left ventricular systolic dys-
function in the general population (Table 5). These au-
thors hypothesized that plasma BNP together with simple
clinical indices would reduce the number of echocardio-
grams and, therefore, the cost of population screening for
left ventricular systolic dysfunction in the general popu-
lation. Screening high-risk individuals by BNP before
echocardiography could reduce the cost per detected case
of left ventricular systolic dysfunction by 26%, for a cost
ratio of 1:20 (BNP/echocardiogram). More reduced costs
(up to 50%) can be predicted for the group of low-risk
individuals (37 ).
The results of a cost-effectiveness analysis, however,
strongly depend on the relative cost of the CNH test
compared with that of echocardiograms, as well as on the
prevalence of HF in the population screened. Unfortu-
nately, these factors can vary considerably among depart-
ments, countries, and healthcare systems; it therefore is
probably necessary that each laboratory/clinical depart-
ment analyzes the cost-effectiveness in its own economic
framework. Furthermore, cost-effectiveness analysis is
also dependent on the sensitivity of the CNH assay for
detecting HF. Cost-effectiveness will improve if more
specific assays are used: this would decrease the number
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of individuals with false-positive (FP) results and, conse-
quently, the number of additional useless investigations.
General Discussion
As reviewed in detail in the previous sections, the authors
of several studies hypothesized that CNH assays may be
clinically useful for the screening and classification of
patients with HF, as prognostic markers in cardiac dis-
ease, for follow-up of patients with HF, and to avoid
unnecessary diagnostic procedures. A critical review
should test whether sufficient experimental data support
these hypotheses. We believe that at present it is very
difficult to answer these questions positively, mainly
because of the problems discussed below.
The first problem is that there is a general lack of good,
primary studies of test evaluations for CNH assays (42 ).
In particular, even some high-quality studies were not
designed with the primary goal of evaluating the diag-
nostic accuracy of CNH assays. Indeed, this aim was
considered only at a post hoc analysis and was assessed
retrospectively in blood samples collected for different
original purposes, even some years before the actual
evaluation of diagnostic accuracy. This may introduce a
significant bias, although its true clinical relevance is
difficult to assess.
A second problem is that a simple and objective
definition of chronic HF is currently impossible because
there are no defined cutoffs for valvular or myocardial
dysfunction or for changes in cardiac output or cardio-
vascular pressures, dimensions, or volumes that can be
used to reliably identify patients with HF (14 ). Instead,
HF is a clinical syndrome characterized by specific symp-
toms (dyspnea and fatigue) and signs (edemas) (14, 43).
Furthermore, it should be emphasized that HF is not
equivalent to cardiomyopathy or to left ventricular dys-
function; these latter terms describe possible structural
reasons for the development of HF (43 ).
Because there is no a objective rule to identify and/or
clinically stratify patients suspected to have HF, the
different groups of investigators used different gold stan-
dards to evaluate the diagnostic accuracy of CNH assays,
including clinical scores. In this case, the patients studied
were stratified and grouped according to clinical severity,
as described by functional classification (usually NYHA
classification; Fig. 2). In other studies, only echocardio-
graphic measurements were used as the gold standard to
determine the accuracy of CNH assays for the diagnosis
of left ventricular dysfunction (and not for the clinical
diagnosis of HF).
It is important to underscore that both mechanical and
neuroendocrine functions contribute to overall cardiovas-
cular function and that, although separate, they represent
interdependent functions mutually affected by many and
complex feed-back mechanisms (4 ). A corollary of this
assumption is that assays of the neuroendocrine system
and clinical investigations of cardiac pump function offer
different, but complementary, information about cardiac
function (4 ). Both mechanical and neuroendocrine func-
tions should always be tested separately by suitable
methods to achieve more complete knowledge of the role
played by the heart in all physiologic and clinical condi-
tions. Therefore, we believe that echocardiographic re-
sults should not be used as the only gold standard for the
evaluation of diagnostic accuracy of CNH assays in pa-
tients with HF.
Comparison of the studies concerning the diagnostic
accuracy of CNH assay was also difficult because differ-
ent populations were enrolled and different immunoas-
says were used. Indeed, diagnostic accuracy (especially
predictive values) is strictly dependent on disease preva-
lence (pretest probability), which evidently varies greatly
according to the clinical setting considered (i.e., screening
for general population, outpatients seen by a general
practitioner, or in primary care, emergency department,
coronary care unit, and other settings). Another factor,
often underestimated, is that the gold standard (which is
not an objective rule, but a clinical synthesis or another
diagnostic test) could vary with disease prevalence, some-
times in a different manner than CNH assays.
In an asymptomatic or low-risk population, the diag-
nostic sensitivity in detecting left ventricular systolic
dysfunction could be suboptimal, especially in women
(8 ). A large number of FP results obtained with CNH
assays in a general asymptomatic population can be
related to the diseases reported in Table 1. Because it is
well known that patients suffering from some endocrino-
logic, metabolic, or renal diseases are at higher risk for
cardiac disease, abnormal CNH assay results could pre-
dict an increased risk for cardiac disease more accurately
and earlier than a standard echocardiographic examina-
tion in some clinical settings.
On the other hand, false-negative (FN) results could be
found in patients on antihypertensive treatment with
antiadrenergic agents or ACE inhibitors, which both re-
duce CNH concentrations. It is well known that these
patients have an overall reduced rate of major cardiac
events or mortality compared with untreated hyperten-
sive patients, who could have similar echocardiographic
abnormalities.
On the contrary, in populations with higher disease
prevalences, the diagnostic sensitivity improves up to
90% or more by selecting appropriate cutoff values in
some clinical settings (Table 5). In this case, a strategy,
called “SnNout”, which maximizes test sensitivity, could
be used to rule out the disease (41 ). Furthermore, CNH
assays generally also have high NPV values (Table 5),
which can also help in excluding the presence of the
disease (i.e., HF) in individual patients. These findings
represent the rationale for choosing CNH assays as part of
the first step for an algorithm for the diagnosis of HF (14 ).
On the other hand, test specificity ranged between 53% to
84% and PPV between 3% and 85% in some studies (Table
5). These data indicate that CNH assays can produce
relatively large numbers of FP results. Consequently,
44 Clerico and Emdin: Diagnostic Accuracy of Cardiac Natriuretic Peptides
many individuals who do not have HF (15–60% of those
with positive test results) may undergo expensive and/or
harmful investigations to rule out the disease or even be
inappropriately labeled as cardiac patients.
Moreover, some data reported in the literature sug-
gested that diagnostic accuracy may significantly vary in
relation to the specific cardiac peptide measured and/or
immunoassay used (29, 52). At present, the different
CNH immunoassays also show greatly different impreci-
sion (27 ). Consequently, it is not clear whether the ob-
served significant variation in diagnostic accuracy is at-
tributable to a difference in the pathophysiologic behavior
of measured peptides and/or in assay performance (27–
29, 51–53, 72). Unfortunately, the authors of some studies
do not clearly indicate the type of immunoassay used to
measure CNHs, and the majority do not report the assay
performance (often not even the reference values) evalu-
ated in their own laboratories.
It is important to note that the diagnostic accuracies of
conventional clinical investigations could be very similar
to those of CNH assays in particular clinical settings. For
example, Nielsen et al. (37 ) reported that a self-reported
questionnaire (including blood pressure measurement)
together with a standard 12-lead ECG (but without echo-
cardiographic examination) had diagnostic accuracy very
similar to that of a BNP assay (sensitivity, 90%; specificity,
56%; PPV, 7%; NPV, 99.3%; Table 5). In another study
(149), clinical judgment had a sensitivity of 49% and
specificity of 96%, whereas a BNP assay (by a POCT
method) had a sensitivity of 90% and specificity of 73% in
determining the diagnosis of HF in patients presenting
with acute dyspnea in an emergency department. More-
over, the AUCs for ROC curves were 0.86 (95% CI,
0.84–0.88), 0.90 (0.88–0.91), and 0.93 (0.92–0.94) for clin-
ical judgment, for BNP at a cutoff of 100 ng/L (28.9
pmol/L), and for the two diagnostic approaches in com-
bination, respectively. These data (37, 149) suggest that
the cost-effectiveness of using CNH assays for the screen-
ing of patients suspected to have HF must be accurately
evaluated before this test can be used routinely in a
particular clinical setting.
Because of these problems, a metaanalysis of all data
available for the evaluation of the diagnostic accuracies of
CNH assays is difficult or even impossible (this type of
analysis is not available in the literature). Moreover, the
review of the overall data reported in the previous sec-
tions of this article indicates that several aspects are still
unsolved; a working list could include:
• There is no nomenclature for CNHs and their related
peptides that is universally accepted and used in the
literature;
• Standardization of CNH immunoassays is lacking, in-
cluding use of the same peptide preparation for dose–
response curve calibration, as well as use of the same
units, references, and cutoff values. Furthermore, the
analytical performance of some immunoassay methods
is not yet well established;
• There are insufficient results concerning which hor-
mone (ANP or BNP) or N-terminal propeptide
(NT-proANP or NT-proBNP) should be assayed. In
particular, the diagnostic accuracies of different immu-
noassay methods are uncertain, as are the clinical set-
tings (i.e., with low or high prevalence of disease) in
which these different assays perform better;
• There are conflicting data concerning the use of CNH
assays as risk markers in patients with cardiovascular
disease, mainly regarding optimal decision limits and
their use in combination with other biochemical mark-
ers, clinical findings, or hemodynamic indices. More-
over, additional work is needed to identify therapies
that may reduce the risk associated with increased CNH
concentrations. Finally, it is not clear whether patients
with increased CNH concentrations should be treated
more aggressively.
• Additional studies are also needed to analyze the clin-
ical relevance of CNH assays in the follow-up of pa-
tients with cardiovascular disease, as well as their
cost-effectiveness in different clinical settings.
Conclusions and Future Perspectives
Much work is still needed to carefully assess the diagnos-
tic accuracies and prognostic values of CNH assays in
cardiac disease. It is important to highlight that these
future studies should be designed to determine what each
CNH assay can provide according to its analytical char-
acteristics. CNH assays cannot replace cardiac imaging,
but both provide independent and complementary infor-
mation for the evaluation of cardiac function and clinical
patient status.
However, taking into account the limitations discussed
above, several well-designed studies have indicated that
CNH assays could be clinically useful for the diagnosis
and characterization of patients with suspected HF. In
particular, increased CNH concentrations in patients with
suspicion of HF are highly suggestive of a correct diag-
nosis. On the other hand, in patients with low CNH
concentrations this diagnosis is unlikely (14 ).
Furthermore, over recent years, several well-designed
studies demonstrated the prognostic relevance of CNH
assays in patients with both HF (25, 33, 87–92) and ACS
(33–35, 38, 60, 72, 86, 94–107). Currently, use as prognos-
tic markers seems to be the main indication for CNH
assays. However, additional evidence regarding the opti-
mal decision limits and their use in combination with
other prognostic and/or risk markers is needed before
they can be accepted in clinical use. Additional work is
also needed to identify therapies that may reduce the risk
associated with increased CNH concentrations.
Generally speaking, BNP and NT-proBNP assays show
better diagnostic accuracy and clinical performance as
prognostic markers than ANP and NT-proANP assays;
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this finding is probably attributable to the prevalent
ventricular production of BNP.
It is important to highlight that the use of CNH assays
as both prognostic markers and guides for tailoring
pharmacologic therapy is in accordance with the patho-
physiologic role played by the CNH system in HF.
Increased CNH concentrations indicate that the neuroen-
docrine system is activated. Several studies have indi-
cated that activation of the neuroendocrine system is the
most important pathophysiologic mechanism for the pro-
gression of HF (16, 150, 151). CNH assays could be used
as a faster, less expensive, and easier way to monitor
activation of the neuroendocrine system than assays for
catecholamines, angiotensin II, endothelins, and cyto-
kines.
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